Compare SPDR Gold Trust (GLD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs BIO-TECHNE Corp — how do they compare? SPDR Gold Trust trades at $365.26, while BIO-TECHNE Corp trades at $71.75 (market cap $11.14B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while SPDR Gold Trust pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals.
| GLD | TECH | |
|---|---|---|
52-Week High | $495.90 | $71.48 |
52-Week Low | $300.96 | $43.31 |
Market Cap | — | $11.14B |
Sector | — | Health |
Enterprise Value | — | $11.22B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD (SPDR Gold Shares ETF) trades at $365.75, down 1.72% amid bearish technical signals with 14 sell indicators. The ETF tracks physical gold prices, currently facing pressure from stabilizing dollar and rate-hike expectations. Recent economic data shows mixed signals with cooling inflation but strong labor market data weighing on gold prices. The fund provides direct exposure to gold bullion with lower volatility compared to mining stocks.
Gold's near-term outlook faces headwinds from potential Fed rate policy and dollar strength, though geopolitical tensions and central bank accumulation provide support. The technical picture suggests consolidation near key support levels with bearish momentum indicators. Investors should monitor Fed policy signals and inflation data for directional catalysts.
Bio-Techne (TECH) trades at $71.69, up 0.65% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, though RSI indicates potential overbought conditions. Fundamentally, revenue held at $1.22B in 2025, but net income fell to $73.40M with margin compression. Analysts are split 50/50 buy/hold with a $67.75 consensus target, below the current price, reflecting acquisition uncertainty.
The outlook hinges on the Merck deal closure at $73.00, offering a 1.8% premium from current levels. Risks include shareholder litigation challenging the transaction's fairness and regulatory approval delays. Without the deal, high P/E of 102.12 and declining profitability pose downside risks. The acquisition provides a near-term floor, but execution volatility remains a concern for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
